Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total neoadjuvant therapy in advanced localized rectal cancer
IRCT20120215009014N431Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluorouracil, capecitabine, oxaliplatin and folinic acid in rectal cancer, sponsored by Hamadan University of Medical Sciences. Primary endpoints: Pathologic complete response, Local recurrence and 2 more. Started Jul 2022; status: completed.
02
Drugs
fluorouracilcapecitabineoxaliplatinfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on IRCT20120215009014N431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N431.